Tirzepatide 7.5 mg: what it costs

7.5 mg is where a lot of programmes quietly start charging you more, and almost nobody warns you before you sign up.

7.5 mg is step 3 of 6 on the tirzepatide ladder, reached around weeks 9-12. An intermediate step on the way to the higher doses. Not a target in itself for most people, though some settle here.

Because this is an early rung, the main cost question is not what 7.5 mg costs today but what happens when you reach the higher doses. Programmes that hold one price across the whole ladder are the ones that make that predictable.

The rung where the bill changes

Dose-tiered pricing means your cost rises as the treatment starts working. We track which programmes hold a single price across the whole ladder and which do not, because over a full titration that is worth more than any advertised discount.

What 7.5 mg is for

7.5 mg is a bridge rather than a destination. It exists so that the jump from 5 mg to 10 mg happens in two manageable steps instead of one large one. Most people pass through it; some find it is where the appetite effect finally becomes reliable and stay. Because it sits between the two doses that carry the trial evidence, there is less published data specific to it than either neighbour.

Side effects at this step tend to be milder than the jump to 5 mg, because your system has adjusted.

What 7.5 mg costs

6 of the providers we track hold a single price at every dose, so 7.5 mg costs the same as the starting dose. They are listed first below because at this rung that is the whole ballgame.

Cheapest flat-rate option at 7.5 mg: Trimi at $125 a month, which is what it charges at every other rung too.

The remaining 14 providers either price by dose or do not publish a flat-rate commitment. Their quoted figures start at $125 a month, but that is the starting-dose price — ask specifically what 7.5 mg will cost before you assume it holds.

Do you need to go higher than 7.5 mg?

Not necessarily. The ladder exists so that you can stop where the medication is working for you, and plenty of people settle below the maximum. Reaching the top dose is not a measure of success, and the trial figures are averages rather than targets.

Is 7.5 mg a real maintenance dose?

It can be, though it is studied less than 5 mg or the higher doses. If it is working for you, that is the relevant evidence. If it is not, it is designed as a stepping stone rather than a stopping point.

Before you spend anything: approved oral GLP-1s start at $149 a month and Medicare drops to $50 in July 2026. Both undercut a large part of this market, and neither is compounded.